The funds will facilitate the clinical progression of ABO-101, the company’s lead therapeutic candidate targeting PH1.

Referred to simply as “RetroArch Open Hardware”, the goal is to develop a fully open source cartridge adapter that will integrate seamlessly with the RetroArch software. Just plug in your ...

Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investorsFinancing extends Arbor’s cash ...